Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALFLEUKEMIAIF13.42024-03-120OAAI
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitorsAMERICAN JOURNAL OF HEMATOLOGYIF9.92024-02-051OAAI
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemiaAMERICAN JOURNAL OF HEMATOLOGYIF9.92024-02-050OAAI
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapyLEUKEMIAIF13.42022-06-0810OAAI
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome studyLEUKEMIAIF13.42022-05-2517OAAI
Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cellsLEUKEMIAIF13.42021-03-267PREAI
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remissionLEUKEMIAIF13.42020-05-2917OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向